Could a lower dose of Alzheimer's drug be just as effective?
NCT ID NCT07505095
First seen Apr 04, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This study looks at whether a lower dose of the medication lecanemab can control Alzheimer's disease as well as the standard dose. Researchers will compare brain scans, thinking tests, and blood markers in 140 people with early-stage Alzheimer's over 18 months. The goal is to find the best dose that balances effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE (AD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Human Subject Research Ethics Committee, 2ndAffiliated Hospital, School of Medicine, Zhejiang University,
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.